1. Home
  2. RACC vs ANIX Comparison

RACC vs ANIX Comparison

Compare RACC & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RACC

Research Alliance Corporation III Class A Ordinary Shares

N/A

Current Price

$21.40

Market Cap

102.8M

Sector

N/A

ML Signal

N/A

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.53

Market Cap

119.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RACC
ANIX
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.8M
119.8M
IPO Year
2026
2013

Fundamental Metrics

Financial Performance
Metric
RACC
ANIX
Price
$21.40
$3.53
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
54.7K
278.2K
Earning Date
N/A
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.39
$2.32
52 Week High
$23.00
$5.46

Technical Indicators

Market Signals
Indicator
RACC
ANIX
Relative Strength Index (RSI) 89.21 57.72
Support Level $10.44 $2.90
Resistance Level N/A $3.53
Average True Range (ATR) 0.97 0.29
MACD 0.46 0.00
Stochastic Oscillator 94.54 55.91

Price Performance

Historical Comparison
RACC
ANIX

About RACC Research Alliance Corporation III Class A Ordinary Shares

Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: